Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPTLC1 | O15269 | 2/20 | 0.64 |
| ▸ | SPTLC2 | O15270 | 2/20 | 0.64 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 2/20 | 0.36 |
| ▸ | FNTB | P49356 | 2/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31618543 | 0.87 | SPTLC1 (0.75) | SPTLC1SPTLC2FAAHEPHX2 | |
| SCHEMBL14190668 | 0.85 | SPTLC1 (0.75) | SPTLC1SPTLC2FAAH | |
| SCHEMBL6804868 | 0.85 | SPTLC1 (0.75) | SPTLC1SPTLC2FAAH | |
| SCHEMBL14190672 | 0.85 | SPTLC1 (0.75) | SPTLC1SPTLC2FAAH | |
| SCHEMBL6748282 | 0.84 | SPTLC1 (0.76) | SPTLC1SPTLC2FAAHCYP3A4CYP2C9 | |
| SCHEMBL10082711 | 0.84 | SPTLC1 (0.76) | SPTLC1SPTLC2FAAHCYP3A4CYP2C9 | |
| SCHEMBL6802874 | 0.84 | SPTLC1 (0.76) | SPTLC1SPTLC2FAAHCYP3A4CYP2C9 | |
| SCHEMBL6804494 | 0.83 | SPTLC1 (0.73) | SPTLC1SPTLC2FAAHCYP1A2CYP3A4 | |
| SCHEMBL12641489 | 0.83 | SPTLC1 (0.73) | SPTLC1SPTLC2FAAHCYP1A2CYP3A4 | |
| SCHEMBL14190638 | 0.83 | SPTLC1 (0.73) | SPTLC1SPTLC2FAAHCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183005-B1 | Pharmaceutical agents for treating HCV infections | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183005-B1 | Pharmaceutical agents for treating HCV infections | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110160252-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF HBV INFECTION | PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160252-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF HBV INFECTION | PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7378446-B2 | Compound having anti-HCV activity and process for producing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-27 | — | — | US | disclosed |
| US-7378446-B2 | Compound having anti-HCV activity and process for producing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160252-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF HBV INFECTION | IFNG, HDGF, HAVCR2 | SPTLC1 4049/4885SPTLC2 4400/4885FAAH 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.